The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Effect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-term Risk of Acute Myocardial Infarction in the Elderly
Abstract
BACKGROUND: Recent debate has emerged regarding the cardiovascular safety of selective cyclooxygenase 2 inhibitors and the possible cardioprotective effect of naproxen sodium. We compared the rates of acute myocardial infarction (AMI) among elderly patients dispensed selective cyclooxygenase 2 inhibitors, naproxen, and nonselective nonnaproxen nonsteroidal anti-inflammatory drugs (NSAIDs). METHODS: We conducted a population-based retrospective cohort study using administrative health care data from Ontario, Canada, from April 1, 1998, to March 31, 2001. We identified NSAID-naive cohorts of subjects aged 66 years and older in whom treatment was initiated with celecoxib (n = 15 271), rofecoxib (n = 12 156), naproxen (n = 5669), and nonnaproxen nonselective NSAIDs (n = 33 868), along with a randomly selected control cohort not exposed to NSAIDs (n = 100 000). Multivariate Cox proportional hazards models were used to compare AMI rates between study drug groups while controlling for potential confounders. RESULTS: Relative to control subjects, the multivariate model showed no significant differences in AMI risk for new users of celecoxib (adjusted rate ratio [aRR], 0.9; 95% confidence interval [CI], 0.7-1.2), rofecoxib (aRR, 1.0; 95% CI, 0.8-1.4), naproxen (aRR, 1.0; 95% CI, 0.6-1.7), or nonnaproxen nonselective NSAIDs (aRR, 1.2; 95% CI, 0.9-1.4). CONCLUSIONS: The findings of this observational study suggest no increase in the short-term risk of AMI among users of selective cyclooxygenase 2 inhibitors as commonly used in clinical practice. Furthermore, the findings do not support a short-term reduced risk of AMI with naproxen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
Schneeweiss, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.9.854 · Cited by 711
Austin, P. C., Daly, P. A., & Tu, J. V. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123839 · Cited by 525
Self-citationCOX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
van Hecken, A., Schwartz, J. I., Depré, M., de Lepeleire, I., Dallob, A., Tanaka, W., Wynants, K., Buntinx, A., Arnout, J., Wong, P. H., et al. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001005 · Cited by 354
Ray, W. A., Stein, C. M., Hall, K., Daugherty, J. R., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07370-1 · Cited by 326
Watson, D. J., Rhodes, T., Cai, B., & Guess, H. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1105 · Cited by 238
Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction
Solomon, D. H., Glynn, R. J., Levin, R., & Avorn, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1099 · Cited by 234
White, W. B., Faich, G., Whelton, A., Maurath, C., Ridge, N. J., Verburg, K. M., Geis, G. S., & Lefkowith, J. B. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02265-2 · Cited by 230
Association Between Naproxen Use and Protection Against Acute Myocardial Infarction
Rahme, E., Pilote, L., & LeLorier, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1111 · Cited by 203
Reicin, A. S., Shapiro, D., SPERLING, R. S., Barr, E., & Yu, Q. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02201-9 · Cited by 136
FitzGerald, G. A. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02234-8 · Cited by 125
Use of Prescription Medications in an Elderly Rural Population: The Movies Project
Lassila, H. C., Stoehr, G. P., Ganguli, M., Seaberg, E. C., Gilby, J. E., Belle, S. H., Echement, D. A., Morand, B. R., & Demers, D. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000604 · Cited by 108
Non-steroidal antiinflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09349-2 · Cited by 49
Jick, S. S. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.9.741.35209 · Cited by 42
Cox, J. L., Mp, M., Chen, E., & Naylor, C. D. (1997) · PubMed · Cited by 34
Cited by
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
Validation of the national health insurance research database with ischemic stroke cases in Taiwan
Cheng, C., Kao, Y. Y., Lin, S., Lee, C., & Lai, M. L. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2087 · Cited by 1,277
A review of uses of health care utilization databases for epidemiologic research on therapeutics
Schneeweiss, S., & Avorn, J. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.012 · Cited by 1,277
Metadata
- Authors
- Mamdani, M., Rochon, P., Juurlink, D. N., Anderson, G. M., Kopp, A., Naglie, G., Austin, P. C., & Laupacis, A.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2003-02-24
- Volume
- 163
- Issue
- 4
- Pages
- 481
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2063252400
- Cited by
- 281
- References
- 19
- FWCI
- 28.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.